Treatment of Psoriatic Arthritis Arthritis treated with disease-modifying antirheumatic drugs (DMARDs—particularly methotrexate), apremilast, and biologic agents (tumor necrosis factor [TNF] - alpha antagonists, ustekinumab, secukinumab, ixekizumab, tofacitinib, abatacept, and guselkumab) For axial disease, biologic agents such as tumor necrosis factor [TNF] - alpha antagonists, secukinumab, ixekizumab, Janus kinase (JAK) inhibitors, and consideration of the IL-12/23 inhibitor ustekinumab Treatment of psoriatic arthritis is directed at controlling skin lesions and at reducing joint inflammation.